---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-018413"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2024-02-22T23:59:59+00:00"
generated_at: "2026-06-05T20:44:01.935490+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kymera Q4 net loss $14.4M, cash $745M; KT-474 Phase 2 data due H1 2025

## Summary
- Net loss $14.4M in Q4, $147.0M for FY2023; collaboration revenue $47.9M Q4, $78.6M FY.
- Cash and investments $745M as of Jan 9, 2024, including $301M from equity offering; runway into H1 2027.
- KT-474 Phase 2 trials in HS and AD started; topline data expected H1 2025; $55M milestone from Sanofi.
- KT-621 STAT6 degrader Phase 1 expected H2 2024; KT-294 TYK2 Phase 1 expected H1 2025; data in 2025.
- Additional Phase 1 data for KT-333 (STAT3) and KT-253 (MDM2) expected in 2024.

## SEC filing metadata
- accession: 0000950170-24-018413
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2024-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000095017024018413/0000950170-24-018413-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000095017024018413/kymr-20240222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-018413
- JSON: https://secwatch.observer/filing/0000950170-24-018413.json
- Plain text: https://secwatch.observer/filing/0000950170-24-018413.txt

## Key facts
- Earnings Releases
  Kymera Therapeutics, Inc. reported financial results for the quarter ended December 31, 2023 and for the fiscal year ended December 31, 2023.
  - Period: the quarter ended December 31, 2023 and for the fiscal year ended December 31, 2023
  - Result: reported results
  source text: On February 22, 2024, Kymera Therapeutics, Inc. announced its financial results for the quarter ended December 31, 2023 and for the fiscal year ended December 31, 2023. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815442/000095017024018413/0000950170-24-018413-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.